2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Domenica Lorusso,Kan Yonemori,Richard G Moore ,Bradley J Monk ,Eva María Guerra Alía ,Sally Baron‐Hay ,Ulus Ali Şanlı ,Ronnie Shapira‐Frommer ,Alessandro D Santin ,David S Miller ,Jodi A Mckenzie ,Isabelle Ray‐Coquard ,Antonio Casado Herráez ,Jie Huang,Helen Mackay,Yong Man Kim,Vicky Makker,Kimio Ushijima,Gianmaria Barresi,Nicoletta Colombo

doi:10.1136/ijgc-2022-esgo.223

2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Domenica Lorusso, Kan Yonemori + Show 18 more

Open Access

https://doi.org/10.1136/ijgc-2022-esgo.223

Copy DOI

#Treatment Of Physician’s Choice #Progression-free Survival HR + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundIn the phase 3 Study 309/KEYNOTE-775 (Makker 2022, NEJM), lenvatinib plus pembrolizumab (L+P) demonstrated statistically and clinically significant improvements in progression-free survival (PFS), overall survival (OS), and objective response rate...

Full Text